Replies to post #4533 on Seelos Therapeutics Inc (SEEL)

[MasterMerlins]

Your right to a certain extent.. A Quarter Cash Burn of $4M-$5M would deplete the Cash on hand in about 5-6 Quarters..!

But.. That would mean NO Revenues Booked to Offset the Cash Burn..

Altough.. I don't expect much from Granisol, Aquoral and even Totect ( which by the way.. I can't find anything that says that the Backlog Issues have been Resolved ).. I do expect them to reflect something from the Abbott Upfront Payment this Quarter..
And Maybe something from the 129 Totect Kits that were Released prior to the FDA shutting the Previous Manufacturing Facility Down.. Also, Revenues from the Diagnostic Kit Sales..

The French Company will not hit the Financial Statements until Q3 2012.. So, Sales Figures will not be Impacted from Scomedica until then.. ( Remember.. They were/are a Profitable Company.. And it is to their Benefit to Continue that way.. As they would get more Apricus Shares if they hit their Financial Milestone..! )..

Also, during the Q3 2012.. We should see something from the BioQuant Sale.. The First Installment of $125 K at the Very least..!

And let's not forget that Dr. Damaj Expects to close on $12 Million in Upfront Payments this Year for Vitaros.. ( Now, I do not know if this Actually means $4 M more in Upfront Payments from Closed Deals or $8 M more in Upfront Payments.. Either way.. It's on top of the Abbott Lab and Sandoz / Novartis Upfronts..! )..

Also, we should get something from Exodos Life Sciences as soon as they get their clinical trials going.. ( I believe they were estimating starting mid 2012.. )

It should be a Very Interesting Rest of the Year..

I personally see Important Events almost every 2 Weeks for a while .. Starting with NEXT Week..!

[eicoman]

Yes, they need those back on market, and they are suppose to be re-launching now the cancer prodcuts, partnership upfront pays are needed to for cash flow next 12 months, they plan on being cash flow positive by end of next year, the French co purchase was a very smart move , if EU Vitaros approval is given then APRI keeps all the cash in France - a key country for Vitaros sales.